<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The activated clotting time (ACT) may be an unreliable monitor of coagulation for patients with the <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We describe a patient with <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> in whom adequate anticoagulation during cardiopulmonary bypass was confirmed by monitoring both the ACT and anti-factor Xa levels </plain></SENT>
<SENT sid="2" pm="."><plain>The cardiopulmonary bypass was uneventful, and there were no thrombotic or <z:mp ids='MP_0001914'>bleeding</z:mp> complications </plain></SENT>
<SENT sid="3" pm="."><plain>The use of anti-factor Xa levels provided confirmation of adequate anticoagulation (and reversal of anticoagulation) that was not possible using the ACT alone </plain></SENT>
</text></document>